Led by a former BioNTech executive, Bambusa Therapeutics (BBTX.US) is heading for NASDAQ to fund clinical trials for its eczema drug.
智通财经2026/10/10 06:21Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Golden Ten Data has learned that Bambusa Therapeutics Inc. (BBTX.US) has submitted an initial public offering application, planning to raise funds to support clinical trials for drugs treating eczema and other inflammatory diseases.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
German central bank official warns: Risk of European debt crisis is rising sharply
智通财经•2026/10/10 07:36
Apple adjusts 2026 fall new device orders, increases iPhone Duo order by 30%
智通财经•2026/10/10 06:36
